NATURAL PRODUCT DRUGS FROM COLD WATER MARINE ORGANISMS

来自冷水海洋生物的天然药物

• 批准号: 2869824
• 负责人: GREGG R DIETZMAN
• 金额: $ 10万
• 依托单位: WHITE POINT SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-01 至 2000-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2869824
• 关键词: aquatic organism; biological products; cell line; cold temperature; cytotoxicity; drug discovery /isolation; drug screening /evaluation; neoplastic cell; saltwater environment

DESCRIPTION (Verbatim from the applicant's abstract): The goal of this project is to pursue the pre-clinical development of 10 active leads with selective cancer cell cytotoxicity. Extracts (320) of 160 biologically diverse temperate and polar marine macroorganisms, representing regions largely unexplored by other discovery programs, were evaluated in a preliminary study. Actives were determined by random screening against a panel of cancer cell lines that compared growth inhibition of the L1210 murine and CCRF-CEM human leukemias versus severe drug insensitive tumors (murine colon 38, murine mammary 410.4, human colon H-116), and compared inhibition of a normal stem cell (CFU-GM) versus the murine and human solid tumor types. Phase I will purify sufficient material using activity-directed isolation methods from frozen archive raw tissue, no recollection is required. Active leads will then be evaluated in an animal model and their chemical structures will be characterized. Phase II will extend the effort by moving actives forward in the drug-development pipeline. The applicant expects that novel compounds with important anti-cancer activities will be discovered by this project. Lead candidates will be developed by White Point BioMarine and its collaborators through solid-tumor animal models, pharmacokinetics, preclinical toxicology and mechanism of action studies, at which time they will be patented and licensed to others for further development. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述（逐字从申请人的摘要）：该项目的目标 是追求10个活性电极导线的临床前开发， 癌细胞毒性。提取物（320）160生物多样性温带 和极地海洋大型生物，代表了大部分未被探索的地区。 其他发现程序，在初步研究中进行了评估。积极分子是 通过对一组癌细胞系进行随机筛选来确定， 比较了L1210小鼠和CCRF-CEM人白血病的生长抑制 与严重的药物不敏感肿瘤（鼠结肠38，鼠乳腺410.4， 人结肠H-116），并比较正常干细胞（CFU-GM）的抑制 与鼠和人实体瘤类型相比。第一阶段将净化足够的 使用活性导向分离方法从冷冻原始档案中分离材料 组织，不需要回忆。然后，将在 将表征动物模型及其化学结构。二期将 通过在药物开发管道中推进活性物质来扩大努力。 本申请人预期具有重要抗癌活性的新化合物 该项目将发现活动。主要候选人将是 由白色点生物海洋公司及其合作者通过实体瘤 动物模型、药代动力学、临床前毒理学和作用机制 研究，届时他们将获得专利，并授权给其他人，以进一步 发展 拟议商业应用：不可用